SCHEMBL21964077

SCHEMBL21964077

CCOC(=O)CN(C(=O)C(C)(C)C)C1CCCN(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 6/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 2/20 0.33
POLB P06746 2/20 0.33
NPC1 O15118 2/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 2/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21964068 0.93 L3MBTL1 (0.35) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL21964207 0.91 L3MBTL1 (0.38) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL21964180 0.89 L3MBTL1 (0.42) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL21964069 0.88 POLB (0.36) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL22011478 0.87 ALDH1A1 (0.43) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL21964127 0.87 L3MBTL1 (0.39) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL28604432 0.84 ALDH1A1 (0.40) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL28919216 0.81 HPGD (0.43) ALDH1A1SMN1; SMN2MEN1KMT2AMAPT
SCHEMBL21964048 0.80 L3MBTL1 (0.39) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL24220741 0.79 ALDH1A1 (0.42) L3MBTL1ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2022-01-27 US disclosed
EP-3880679-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS The University Of Sheffield (GB) 2021-09-22 EP disclosed
WO-2020099882-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220023281-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, AGTR1 L3MBTL1 4019/4885ALDH1A1 1456/4885SMN1; SMN2 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.